Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology - Reuters
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQbUNLeXg3N3k2RHR6T1ozbUI0MFd3ekE1YS1sNmxuWjZxeDhSZ1lDb1NqWXBsbXRaMktEcWV6b3dKREtyMEVCcy12dlI3cGtoVk1xYUFVbjVsNXVyclRIVXdvMFBWZG1UN21JLUZkcVpEZjdvbjRlU3YzUS1hd2xqYzJSZVFSZF9LVVBtY01Demh0U094NzE4a0xtaUNONHlqcTVqZWlybGdYYWlEVzlpaHFJZV80NkY2N1NQR1E2a1FIaFRwT3c?oc=5" target="_blank">Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Boots has a new owner: Three ways it could affect you
The stalwart of Britain's High Street has been sold to a Canadian billionaire family. What will that mean for you?
October 9, 2026 at 11:01 PMDental firm vVardis reveals revenue surge in US IPO filing - Reuters
Dental firm vVardis reveals revenue surge in US IPO filing Reuters
October 9, 2026 at 07:31 PM'People don't think recycling at work is part of their job description'
Unclear labelling as well as a lack of recycling facilities at work or in public-facing businesses is an issue.
October 9, 2026 at 07:11 PMBASF considers raising offer for Evonik, sources say - Reuters
BASF considers raising offer for Evonik, sources say Reuters
October 9, 2026 at 02:02 PMReport highlights flaws in ADHD and autism care
There is a risk of people being over-diagnosed with ADHD and autism, an official review in England has found.
October 9, 2026 at 01:52 PMHumana surges after topping 2027 Medicare star ratings - Reuters
Humana surges after topping 2027 Medicare star ratings Reuters
October 9, 2026 at 01:33 PM